Table III.
miR-186 expression is associated with metastatic recurrence risk in GIST patients.
| Features | OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
|---|---|---|---|---|
| Tumor location | ||||
| Stomach | 1 | |||
| Other (intestine, esophagus, colon) | 0.78 (0.16–3.85) | 0.76 | 3.12 (0.47–20.9)a | 0.24 |
| Risk classification | ||||
| Low or intermediate risk | 1 | |||
| High risk | 12.8 (3.59–45.8) | <0.001 | 13.4 (3.47–51.7)b | <0.001 |
| miR-186/U6 | ||||
| >0.172 | 1 | |||
| ≤0.172 | 4.04 (1.30–12.6) | <0.05 | 3.84 (1.02–14.4)c | <0.05 |
a
Risk classification and miR-186/U6 adjusted OR.
b
Tumor location and miR-186/U6 adjusted OR.
c
Tumor location and risk classification adjusted OR. miR, microRNA; GIST, gastrointestinal stromal tumor; OR, odds ratio; CI, confidence interval.